Compare Extra Space Storage, Inc. (EXR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Merck & Co., Inc. — how do they compare? Extra Space Storage, Inc. trades at $147.11 (market cap $30.96B), while Merck & Co., Inc. trades at $132.84 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 10.4× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| EXR | MRK | |
|---|---|---|
Market Cap | $30.96B | $321.77B |
Sector | Real Estate | Health |
52-Week High | $152.85 | $131.84 |
52-Week Low | $126.67 | $77.60 |
Enterprise Value | $44.68B | $368.53B |
Dividend Yield | 4.42% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $146.66, down 1.93% on the day, with a bearish technical signal and neutral oscillators. The company reported strong Q2 2026 earnings, beating FFO estimates and raising full-year guidance, with revenue growth and solid same-store NOI performance. Analyst consensus is a 'Hold' with a $157.25 price target, indicating modest upside potential from current levels.
Outlook remains stable with steady revenue and earnings growth supported by acquisitions and resilient demand, though new supply and higher debt pose headwinds. Risks include competitive pressures and interest rate sensitivity, but the secure 4.3% dividend yield and strong balance sheet provide downside protection for income-focused investors.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
